Syntara Limited

CHIA:SNT Stock Report

Market Cap: AU$123.2m

Syntara Valuation

Is SNT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNT?

Key metric: As SNT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SNT. This is calculated by dividing SNT's market cap by their current revenue.
What is SNT's PS Ratio?
PS Ratio21.4x
SalesAU$5.76m
Market CapAU$123.17m

Price to Sales Ratio vs Peers

How does SNT's PS Ratio compare to its peers?

The above table shows the PS ratio for SNT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.9x
VLS Vita Life Sciences
1.4xn/aAU$108.8m
IDT IDT Australia
3.4xn/aAU$47.3m
MYX Mayne Pharma Group
1x9.3%AU$370.5m
RCE Recce Pharmaceuticals
21.9x-13.1%AU$110.1m
SNT Syntara
21.4x1.7%AU$123.2m

Price-To-Sales vs Peers: SNT is expensive based on its Price-To-Sales Ratio (21.4x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does SNT's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

16 CompaniesPrice / SalesEstimated GrowthMarket Cap
MYX Mayne Pharma Group
1x9.3%US$229.26m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.4xn/aUS$67.31m
MVP Medical Developments International
1.5x14.4%US$30.67m
SNT 21.4xIndustry Avg. 4.7xNo. of Companies16PS01224364860+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SNT is expensive based on its Price-To-Sales Ratio (21.4x) compared to the Australian Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is SNT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.4x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: SNT is expensive based on its Price-To-Sales Ratio (21.4x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.077
AU$0.16
+107.8%
25.0%AU$0.20AU$0.12n/a2
Jan ’26AU$0.081
AU$0.16
+97.5%
25.0%AU$0.20AU$0.12n/a2
Feb ’25AU$0.019
AU$0.22
+1,057.9%
54.5%AU$0.34AU$0.10n/a2
Jan ’25n/a
AU$0.22
0%
54.5%AU$0.34AU$0.10AU$0.0812
Dec ’24AU$0.03
AU$0.20
+577.8%
49.6%AU$0.34AU$0.10AU$0.0553
Nov ’24AU$0.033
AU$0.20
+516.2%
49.6%AU$0.34AU$0.10AU$0.0413
Oct ’24AU$0.032
AU$0.19
+493.8%
56.2%AU$0.34AU$0.10AU$0.0443
Sep ’24AU$0.041
AU$0.12
+180.5%
13.0%AU$0.13AU$0.10AU$0.0352
Aug ’24AU$0.055
AU$0.17
+209.1%
41.2%AU$0.24AU$0.10AU$0.0342
Jul ’24AU$0.044
AU$0.17
+286.4%
41.2%AU$0.24AU$0.10AU$0.0232
Jun ’24AU$0.054
AU$0.17
+214.8%
41.2%AU$0.24AU$0.10AU$0.022
May ’24AU$0.061
AU$0.17
+178.7%
41.2%AU$0.24AU$0.10AU$0.0172
Apr ’24AU$0.041
AU$0.17
+314.6%
41.2%AU$0.24AU$0.10AU$0.0212
Analyst Price Target
Consensus Narrative from 2 Analysts
AU$0.16
Fair Value
51.2% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:46
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syntara Limited is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Anubhav SaxenaBell Potter
Thomas WakimBell Potter